Vogt Frederick G 4

4 · IOVANCE BIOTHERAPEUTICS, INC. · Filed Mar 4, 2026

Form 4

Period: 2026-03-02

DirectorInterim CEO & General Counsel

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-03-02+52,087→ 516,609 total
Tax Payment
Common Stock
[F2][F3]
2026-03-02$3.79/sh−22,809$86,446→ 493,800 total
Exercise/Conversion
Restricted Stock Units
[F4][F5][F6]
2026-03-02−41,669→ 166,675 total
→ Common stock (41,669 underlying)
Exercise/Conversion
Restricted Stock Units
[F4][F5][F7]
2026-03-02−10,418→ 0 total
→ Common stock (10,418 underlying)

Footnotes (7)

[F1]Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
[F2]Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
[F3]Represents common stock remaining after deducting the common stock withheld for taxes.
[F4]Each RSU represents a contingent right to receive one share of the Issuer's common stock.
[F5]The remaining RSUs will vest in equal quarterly installments.
[F6]Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person.
[F7]Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person.

Signature

/s/ Frederick G. Vogt|2026-03-04

Documents

1 file